Maternal Obesity Increases Risk for Early-Onset Neonatal Bacterial Sepsis
In a population-based study, risk for early-onset neonatal bacterial sepsis among newborns increased with maternal body mass index.
All articles by Jessica Nye, PhD
Study Finds Vancomycin Increased Risk for Cytomegalovirus Reactivation After Hematopoietic Cell Transplant
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Acute Liver Injury Prevalent in Patients with COVID-19
Researchers observed the presence of acute liver injury caused by COVID-19 in patients at multiple hospitals in China.
Fecal Microbiota Transplant Improved Clinical Outcomes and Decolonized Multi-Drug Resistant Organisms
Fecal microbiota transplant (FMT) appears safe in decolonizing multi-drug resistant organisms (MDRO) from intestinal reservoirs in affected patients, even those who are highly immunosuppressed.
New Guidance for Commencing IBD Treatment During the COVID-19 Pandemic
Patients with IBD should not alter their treatment during the COVID-19 pandemic; however, starting a new treatment regimen should be avoided.
High H pylori Eradication Rate with Rifabutin-Based Therapy
A novel rifabutin-based therapy (RHB-105) may be a potential first-line defense against Helicobacter pylori (H. pylori) infection.
Good Prognosis for Patients with Inflammatory Bowel Disease and COVID-19
Patients with inflammatory bowel disease (IBD) who tested positive for SARS-CoV-2 had a good overall prognosis, despite IBD maintenance treatment.
Changes to Normal Gastrointestinal Care During the COVID-19 Pandemic
The COVID-19 pandemic has caused physicians in the New York area to reevaluate how they care for patients with gastrointestinal (GI) diseases.
Bezlotoxumab Effective for Treating Recurrent Clostridioides difficile Infection
Bezlotoxumab, both alone and in combination with actoxumab, was effective in preventing recurrent Clostridioides difficile infection without increased risk for adverse events.
Dual Therapy With Vonoprazan, Amoxicillin Effective For Helicobacter pylori
Dual therapy with vonoprazan and low-dose amoxicillin had similar efficacy to triple-drug treatment for the eradication of Helicobacter pylori.
-
Loading...
-
Loading...
Next post in Antibiotics, Antimicrobial Resistance
